However, the overall response rate for PD-1 inhibitor therapy is approximately 15–20% in unselected patients with NSCLC, and between 15% and 45% in patients with PD-L1-expressing NSCLC [4]. Here, PDCD1 is linked to non-small cell lung carcinoma.